The Clinicopathologic Characteristics and Clinical Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer

Title
The Clinicopathologic Characteristics and Clinical Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer
Author(s)
이수정강수환배영경전영산[전영산]
Keywords
TAMOXIFEN; TUMOR; PROGNOSIS; ENTITY; WOMEN
Issue Date
201003
Publisher
KOREAN BREAST CANCER SOC
Citation
JOURNAL OF BREAST CANCER, v.13, no.1, pp.74 - 82
Abstract
Purpose The aims of this study were to evaluate the clinicopathologic characteristics and the prognosis of patients with estrogen receptor negative/progesterone receptor positive (ER-/PR+) breast cancer Methods: One thousand five hundred seventy patients were stratified according to ER/PR phenotype and our study focused on the ER-/PR+ phenotype The clinicopathologic characteristics and the prognosis of patients with the ER-/PR+ phenotype were compared with those of patients with ER+ (ER+/PR- or ER+/PR+) breast cancer. Results The mean age at diagnosis was 47 1 years (range, 20-88) and the mean follow-up was 65 2 months The horjmone receptor phenotype was ER-/PR+ in 75 cases (4.8%) and ER+ (ER+/PR+ or ER+/PR-) in 917 cases (58 4%) A patient age <50 (p=0.001), a high histologic grade (p=0.004) and C-erbB2 overexpression (p=0 006) were more frequent for the patients with the ER-/PR+ tumors. There was a significant difference between the two groups for the mean age (p<0 001) The 5 year and 10 year disease-free survival (DFS) rates of the ER-/PR+ group were 67 2% and 55.3%, respectively, and those of the ER+ group were 84 9% and 73 1%, respectively (p<0.001). The 5 year and 10 year overall survival (OS) of the ER-/PR+ group were 824% and 62 6%, respectively, and those of ER+ group were 93.4% and 83.3%, respectively (p=0.001) In the under 50 year old patients, the 5 year DFS and OS of the ER-/PR+ group were 67 5% and 85.8%. respectively, and those of ER+ group were 86.3% and 95 8%, respectively. There were significant differences between two groups for the DFS and OS (p<0.001) Conclusion: ER-/PR+ tumors have more aggressive clinioopathologic features than ER+ tumors. Furthermore, in the under 50 year old patients, ER-/PR+ tumors showed a worse prognosis than did the ER+ tumors Consequently, treatment modality and the prognosis of the patients with ER-/PR+ tumors probably need to be altered from those of the patients with ER+ tumors
URI
http://hdl.handle.net/YU.REPOSITORY/22807http://dx.doi.org/10.4048/jbc.2010.13.1.74
ISSN
1738-6756
Appears in Collections:
의과대학 > 성형외과학교실 > Articles
의과대학 > 병리학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE